D-0921-2017 Class II Terminated

Recalled by Lucid Pharma LLC — East Brunswick, NJ

FDA drug recall D-0921-2017 was initiated by Lucid Pharma LLC on Jun 1, 2017 and is designated Class II. Reason for recall: Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules. The recall status is terminated (terminated Sep 25, 2019). Affected quantity: a) 44168 bottles; b) 24960 bottles.

Recall details

Product Type
Drugs
Report Date
Jun 28, 2017
Initiation Date
Jun 1, 2017
Termination Date
Sep 25, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
a) 44168 bottles; b) 24960 bottles

Product description

Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg, packaged in a) 30-count bottles (NDC 52343-132-30) and b) 90-count bottles (NDC 52343-132-90), Rx only, Distributed by: Lucid Pharma LLC, 2 Tower Center Blvd, Suite-1101-B, East Brunswick, NJ 08816 USA.

Reason for recall

Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules.

Distribution pattern

Nationwide in the USA

Code information

Lot #: a) V17516045-A, Exp 08/18; b) V17516047-A 09/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0921-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0921-2017. Report a data issue: hello@regdatalab.com.